Yamaura K, Nelson A L, Nishimura H, Rutledge J C, Ravuri S K, Bahney C, Philippon M J, Huard J
Center for Regenerative and Personalized Medicine, Steadman Philippon Research Institute, Vail, CO, USA; Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Center for Regenerative and Personalized Medicine, Steadman Philippon Research Institute, Vail, CO, USA.
Osteoarthritis Cartilage. 2023 Apr;31(4):435-446. doi: 10.1016/j.joca.2022.11.014. Epub 2022 Dec 28.
The aim of this study is to analyze the latest evidence on the effects of losartan or Ang II receptor antagonists on cartilage repair, with a focus on their clinical relevance.
The PubMed, Embase, and Cochrane Library databases were searched up to November 12th 2021 to evaluate the effects of losartan or Ang II receptor antagonists on cartilage repair in in vitro studies and in vivo animal studies. Study design, sample characteristics, treatment type, duration, and outcomes were analyzed. The risk of bias and the quality of the eligible studies were assessed using the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) risk of bias assessment tool and Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies (CAMARADES).
A total of 12 studies were included in this systematic review. Of the 12 eligible studies, two studies were in vitro human studies, three studies were in vitro animal studies, one study was an in vitro human and animal study, and six studies were in vivo animal studies. The risk bias and quality assessments were predominantly classified as moderate. Since meta-analysis was difficult due to differences in treatment type, dosage, route of administration, and method of outcome assessment among the eligible studies, qualitative evaluation was conducted for each study.
Both in vitro and in vivo studies provide evidence to demonstrate beneficial effects of Ang II receptor antagonists on osteoarthritis and cartilage defect models across animal species.
本研究旨在分析氯沙坦或血管紧张素II受体拮抗剂对软骨修复作用的最新证据,重点关注其临床相关性。
检索截至2021年11月12日的PubMed、Embase和Cochrane图书馆数据库,以评估氯沙坦或血管紧张素II受体拮抗剂在体外研究和体内动物研究中对软骨修复的作用。分析研究设计、样本特征、治疗类型、持续时间和结果。使用实验动物系统评价中心(SYRCLE)偏倚风险评估工具和实验研究动物数据的Meta分析与综述协作方法(CAMARADES)评估纳入研究的偏倚风险和质量。
本系统评价共纳入12项研究。在这12项符合条件的研究中,两项为体外人体研究,三项为体外动物研究,一项为体外人体和动物研究,六项为体内动物研究。偏倚风险和质量评估主要归类为中等。由于符合条件的研究在治疗类型、剂量、给药途径和结果评估方法上存在差异,难以进行Meta分析,因此对每项研究进行了定性评价。
体外和体内研究均提供证据表明血管紧张素II受体拮抗剂对不同动物物种的骨关节炎和软骨缺损模型具有有益作用。